Pieter E Postmus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6115760/publications.pdf

Version: 2024-02-01

176 papers

17,493 citations

20817 60 h-index 130 g-index

176 all docs

176 docs citations

176 times ranked

14401 citing authors

#	Article	IF	CITATIONS
1	Development and validation of a supervised deep learning algorithm for automated wholeâ€slide programmed deathâ€ligand 1 tumour proportion score assessment in nonâ€small cell lung cancer. Histopathology, 2022, 80, 635-647.	2.9	21
2	Natural Course of Cysts in Birt-Hogg-Dubé Syndrome. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1474-1475.	5.6	0
3	High expression of cell adhesion molecule 2 unfavorably impacts survival in non-small cell lung cancer patients with brain metastases. Journal of Thoracic Disease, 2021, 13, 2437-2446.	1.4	O
4	The prognostic value of the tumor-stroma ratio in squamous cell lung cancer, a cohort study. Cancer Treatment and Research Communications, 2020, 25, 100247.	1.7	9
5	Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report. Journal of Thoracic Oncology, 2019, 14, 2109-2119.	1.1	189
6	Renal imaging in 199 Dutch patients with Birt-Hogg-Dub \tilde{A} \otimes syndrome: Screening compliance and outcome. PLoS ONE, 2019, 14, e0212952.	2.5	17
7	Brain metastases: costs for care need to be spend more effectively!. Annals of Palliative Medicine, 2019, 8, 207-209.	1.2	O
8	Changing health care costs for NSCLC, what does it mean?. Lung Cancer, 2018, 117, 62-63.	2.0	2
9	Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. Future Oncology, 2018, 14, 2415-2431.	2.4	24
10	Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study. OncoTargets and Therapy, 2018, Volume 11, 4573-4582.	2.0	15
11	MA08.06 Impact of Depth of Response (DpR) on Survival in Patients with Advanced NSCLC Treated with First-Line Chemotherapy. Journal of Thoracic Oncology, 2017, 12, S387-S388.	1.1	4
12	Prophylactic cranial irradiation for stage IV small cell lung cancer, live longer or reduce morbidity of brain metastases?. Journal of Thoracic Disease, 2017, 9, 3572-3575.	1.4	3
13	Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis?. Familial Cancer, 2016, 15, 297-300.	1.9	3
14	Detecting resistance in EGFR-mutated non-small-cell lung cancer after clonal selection through targeted therapy. Personalized Medicine, 2015, 12, 63-66.	1.5	1
15	Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?. Lung Cancer, 2015, 89, 19-26.	2.0	7
16	Prevalence of Birt–Hogg–Dubé syndrome in patients with apparently primary spontaneous pneumothorax. European Respiratory Journal, 2015, 45, 1191-1194.	6.7	70
17	Long-term follow-up after first-line bronchoscopic therapy in patients with bronchial carcinoids. Thorax, 2015, 70, 468-472.	5.6	53
18	Close Surveillance with Long-Term Follow-up of Subjects with Preinvasive Endobronchial Lesions. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1483-1489.	5.6	35

#	Article	IF	CITATIONS
19	Renal cell cancer (RCC) due to Birt-Hogg-Dubé syndrome. Results of initial imaging and follow-up among $164 < i > FLCN < i > mutation carriers and outcome of 22 cases with RCC Journal of Clinical Oncology, 2015, 33, e15579-e15579.$	1.6	O
20	Benefit of a second opinion: From metastatic disease to resectable lung cancer with sarcoid-like reaction. Respiratory Medicine Case Reports, 2014, 13, 26-27.	0.4	0
21	Facial Fibrofolliculomas as Indicator for Renal Cell Cancer. Japanese Journal of Clinical Oncology, 2014, 44, 609-610.	1.3	0
22	DNA copy number aberrations in endobronchial lesions: a validated predictor for cancer. Thorax, 2014, 69, 451-457.	5.6	14
23	Retrospective evaluation of thromboembolic events in patients with non-small cell lung cancer treated with platinum-based chemotherapy. Lung Cancer, 2014, 86, 73-77.	2.0	27
24	Spontaneous pneumothorax as indicator for Birt-Hogg-Dub \tilde{A} \otimes syndrome in paediatric patients. BMC Pediatrics, 2014, 14, 171.	1.7	14
25	Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Lung Cancer, 2014, 85, 19-24.	2.0	185
26	Why Do Patients and Caregivers Seek Answers From the Internet and Online Lung Specialists? A Qualitative Study. Journal of Medical Internet Research, 2014, 16, e37.	4.3	31
27	Benefit of a Second Opinion for Lung Cancer: No Metastasis to the Kidney but a Synchronous Primary Renal Neoplasm. Case Reports in Oncology, 2014, 7, 122-125.	0.7	4
28	Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 547-556.	2.8	18
29	Right ventricular oxygen supply parameters are decreased in human and experimental pulmonary hypertension. Journal of Heart and Lung Transplantation, 2013, 32, 231-240.	0.6	53
30	EGFR mutation analysis in sputum of lung cancer patients: A multitechnique study. Lung Cancer, 2013, 82, 38-43.	2.0	32
31	Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treatment Reviews, 2013, 39, 252-260.	7.7	68
32	Ventilator-Associated Pneumothorax: Drainage Is Not Always Necessary. Respiration, 2013, 85, 365-366.	2.6	0
33	A de novo FLCN mutation in a patient with spontaneous pneumothorax and renal cancer; a clinical and molecular evaluation. Familial Cancer, 2013, 12, 373-379.	1.9	19
34	Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography. Clinical Cancer Research, 2013, 19, 4163-4173.	7.0	58
35	Can quantifying free-circulating DNA in plasma be used to identify subjects with high-grade pre-invasive endobronchial lesions?. Oncology Letters, 2013, 5, 1591-1594.	1.8	3
36	Development of [11C]erlotinib Positron Emission Tomography for <i>In Vivo</i> Evaluation of EGF Receptor Mutational Status. Clinical Cancer Research, 2013, 19, 183-193.	7.0	117

#	Article	IF	CITATIONS
37	The Stage Classification of Lung Cancer. Chest, 2013, 143, e1915-e210S.	0.8	135
38	Benefit of a Second Opinion: Intrapulmonary Metastases or Multiple Primary Tumors?. Journal of Thoracic Oncology, 2013, 8, e54-e56.	1.1	3
39	CA184-104: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) with paclitaxel/carboplatin (PC) versus placebo with PC in patients (pts) with stage IV/recurrent non-small cell lung cancer (NSCLC) of squamous histology Journal of Clinical Oncology, 2013, 31, TPS8117-TPS8117.	1.6	2
40	Website Visitors Asking Questions Online to Lung Cancer Specialists: What Do They Want To Know?. Interactive Journal of Medical Research, 2013, 2, e15.	1.4	9
41	Reflections on the 14th World Conference on Lung Cancer: A European Perspective. Oncologist, 2012, 17, 463-465.	3.7	0
42	Prolonged sampling of spontaneous sputum improves sensitivity of hypermethylation analysis for lung cancer. Journal of Clinical Pathology, 2012, 65, 541-545.	2.0	20
43	Bisoprolol Delays Progression Towards Right Heart Failure in Experimental Pulmonary Hypertension. Circulation: Heart Failure, 2012, 5, 97-105.	3.9	184
44	An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary?. Journal of Thoracic Oncology, 2012, 7, e3-e5.	1.1	2
45	Benefit of a Second Opinion for Lung Cancer: No Recurrent Disease, but Infection. Journal of Thoracic Oncology, 2012, 7, e6-e7.	1.1	1
46	Negative NKX2-1 (TTF-1) as Temporary Surrogate Marker for Treatment Selection During EGFR-Mutation Analysis in Patients with Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1522-1527.	1.1	26
47	Tumor Cavitation in Patients With Stage III Non–Small-Cell Lung Cancer Undergoing Concurrent Chemoradiotherapy: Incidence and Outcomes. Journal of Thoracic Oncology, 2012, 7, 1271-1275.	1.1	26
48	Progressive Changes in Right Ventricular Geometric Shortening and Long-term Survival in Pulmonary Arterial Hypertension. Chest, 2012, 141, 935-943.	0.8	121
49	Ventilatory and Cardiocirculatory Exercise Profiles in COPD. Chest, 2012, 142, 1166-1174.	0.8	122
50	Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs. Cancer Cell, 2012, 21, 82-91.	16.8	307
51	Comprehensive CADM1 promoter methylation analysis in NSCLC and normal lung specimens. Lung Cancer, 2011, 72, 316-321.	2.0	6
52	Clinically Significant Change in Stroke Volume in Pulmonary Hypertension. Chest, 2011, 139, 1003-1009.	0.8	100
53	Usefulness of Serial N-Terminal Pro–B-Type Natriuretic Peptide Measurements for Determining Prognosis in Patients With Pulmonary Arterial Hypertension. American Journal of Cardiology, 2011, 108, 1645-1650.	1.6	85
54	Time for reappraisal of extracranial treatment options?. Cancer, 2011, 117, 597-605.	4.1	17

#	Article	IF	CITATIONS
55	DNA Copy Number Alterations in Endobronchial Squamous Metaplastic Lesions Predict Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 948-956.	5.6	38
56	Prolonged right ventricular post-systolic isovolumic period in pulmonary arterial hypertension is not a reflection of diastolic dysfunction. Heart, 2011, 97, 473-478.	2.9	58
57	Side-Effects of Long-Term Administration of Erlotinib in Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1477-1480.	1.1	40
58	Prognostic value of hTERT mRNA expression in surgical samples of lung cancer patients: the European Early Lung Cancer Project. International Journal of Oncology, 2010, 37, 455-61.	3.3	8
59	Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report. Journal of Thoracic Oncology, 2010, 5, 554-557.	1.1	26
60	Sorafenib in Patients with Advanced Non-small Cell Lung Cancer that Harbor K-Ras Mutations: A Brief Report. Journal of Thoracic Oncology, 2010, 5, 719-720.	1.1	37
61	The Finding of Premalignant Lesions is Not Associated with Smoking Cessation in Chemoprevention Study Volunteers. Journal of Thoracic Oncology, 2010, 5, 1240-1245.	1.1	3
62	Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?. European Radiology, 2010, 20, 2890-2898.	4.5	87
63	Quantitative Parametric Perfusion Images Using ¹⁵ O-Labeled Water and a Clinical PET/CT Scanner: Test–Retest Variability in Lung Cancer. Journal of Nuclear Medicine, 2010, 51, 1684-1690.	5.0	42
64	A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-NaÃ⁻ve Patients with Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research, 2010, 16, 3078-3087.	7.0	82
65	Right Ventricular Oscillatory Power Is a Constant Fraction of Total Power Irrespective of Pulmonary Artery Pressure. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1315-1320.	5.6	120
66	Progressive Dilatation of the Main Pulmonary Artery Is a Characteristic of Pulmonary Arterial Hypertension and Is Not Related to Changes in Pressure. Chest, 2010, 138, 1395-1401.	0.8	104
67	Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era. Journal of Heart and Lung Transplantation, 2010, 29, 1150-1158.	0.6	9
68	Color Fluorescence Ratio for Detection of Bronchial Dysplasia and Carcinoma <i>In situ</i> Clinical Cancer Research, 2009, 15, 4700-4705.	7.0	45
69	The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 1049-1059.	1.1	435
70	Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H200-H207.	3.2	36
71	Evaluation of a treatment strategy for optimising preoperative chemoradiotherapy in stage III non-small-cell lung cancerâ [†] †â [†] †. European Journal of Cardio-thoracic Surgery, 2009, 36, 1052-1057.	1.4	7
72	Prophylactic Cranial Irradiation in Extensive Disease Small-Cell Lung Cancer: Short-Term Health-Related Quality of Life and Patient Reported Symptoms—Results of an International Phase III Randomized Controlled Trial by the EORTC Radiation Oncology and Lung Cancer Groups. Journal of Clinical Oncology, 2009, 27, 78-84.	1.6	240

#	Article	IF	CITATIONS
73	Predictors of mortality in inoperable chronic thromboembolic pulmonary hypertension. Respiratory Medicine, 2009, 103, 1013-1019.	2.9	39
74	Addition of Prostanoids in Pulmonary Hypertension Deteriorating on Oral Therapy. Journal of Heart and Lung Transplantation, 2009, 28, 280-284.	0.6	18
75	Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands. Lung Cancer, 2009, 64, 110-116.	2.0	34
76	The IASLC Lung Cancer Staging Project: Data Elements for the Prospective Project. Journal of Thoracic Oncology, 2009, 4, 679-683.	1.1	107
77	Dramatic Response to Low-Dose Erlotinib of Epidermal Growth Factor Receptor Mutation-Positive Recurrent Non-small Cell Lung Cancer After Severe Cutaneous Toxicity. Journal of Thoracic Oncology, 2009, 4, 1585-1586.	1.1	22
78	Non-invasive stroke volume assessment in patients with pulmonary arterial hypertension: left-sided data mandatory. Journal of Cardiovascular Magnetic Resonance, 2008, 10, 51.	3.3	58
79	Birt-Hogg-Dubé Syndrome: Clinical and Genetic Studies of 20 Families. Journal of Investigative Dermatology, 2008, 128, 45-49.	0.7	88
80	CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone. Lung Cancer, 2008, 60, 57-61.	2.0	22
81	Primary lung cancer after treatment of head and neck cancer without lymph node metastasis: Is there a role for autofluorescence bronchoscopy?. Lung Cancer, 2008, 62, 309-315.	2.0	16
82	Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. Pulmonary Pharmacology and Therapeutics, 2008, 21, 558-564.	2.6	60
83	Screening and early diagnosis in lung cancer. Expert Review of Anticancer Therapy, 2008, 8, 1529-1531.	2.4	4
84	Cardiopulmonary Exercise Test Characteristics in Patients with Chronic Obstructive Pulmonary Disease and Associated Pulmonary Hypertension. Respiration, 2008, 76, 160-167.	2.6	77
85	Pulmonary vascular resistance and compliance stay inversely related during treatment of pulmonary hypertension. European Heart Journal, 2008, 29, 1688-1695.	2.2	240
86	Exercise Testing to Estimate Survival in Pulmonary Hypertension. Medicine and Science in Sports and Exercise, 2008, 40, 1725-1732.	0.4	129
87	The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours. Journal of Thoracic Oncology, 2007, 2, 706-714.	1.1	3,185
88	Right coronary artery flow impairment in patients with pulmonary hypertension. European Heart Journal, 2007, 29, 120-127.	2.2	207
89	Right Ventricular Diastolic Dysfunction and the Acute Effects of Sildenafil in Pulmonary Hypertension Patients. Chest, 2007, 132, 11-17.	0.8	138
90	Stroke volume response during exercise measured by acetylene uptake and MRI. Physiological Measurement, 2007, 28, 1-11.	2.1	470

#	Article	IF	Citations
91	The Influence of Fluticasone Inhalation on Markers of Carcinogenesis in Bronchial Epithelium. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 1061-1065.	5. 6	19
92	Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. European Heart Journal, 2007, 28, 1250-1257.	2.2	666
93	Influence of Introduction of Positron Emission Tomography on Adherence to Mediastinal Staging Protocols and Performance of Mediastinoscopy. Journal of Oncology Practice, 2007, 3, 242-247.	2.5	0
94	A Web Site on Lung Cancer: Who Are the Users and What Are They Looking For?. Journal of Thoracic Oncology, 2007, 2, 813-818.	1.1	17
95	A 31-Year-Old Man With Hemoptysis at High Altitude and Abnormal Hepatic Biochemistry Tests. Chest, 2007, 132, 1088-1092.	0.8	6
96	Noninvasively Assessed Pulmonary Artery Stiffness Predicts Mortality in Pulmonary Arterial Hypertension. Chest, 2007, 132, 1906-1912.	0.8	352
97	Magnetic resonance and nuclear imaging of the right ventricle in pulmonary arterial hypertension. Country Review Ukraine, 2007, 9, H29-H34.	0.8	5
98	The IASLC Lung Cancer Staging Project: Proposals for Revision of the M Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification of Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 686-693.	1.1	895
99	The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the Tumor, Node, Metastasis Classification for Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 1067-1077.	1.1	503
100	Cardiac Function and Position More Than 5 Years After Pneumonectomy. Annals of Thoracic Surgery, 2007, 83, 1986-1992.	1.3	45
101	Phase I Study of Aerosolized SLIT Cisplatin in the Treatment of Patients with Carcinoma of the Lung. Clinical Cancer Research, 2007, 13, 2414-2421.	7.0	150
102	Dual digital video-autofluorescence imaging for detection of pre-neoplastic lesions. Lung Cancer, 2007, 58, 44-49.	2.0	46
103	Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer. New England Journal of Medicine, 2007, 357, 664-672.	27.0	990
104	Initial bronchoscopic treatment for patients with intraluminal bronchial carcinoids. Journal of Thoracic and Cardiovascular Surgery, 2007, 133, 973-978.	0.8	79
105	Effects on Smoking Cessation: Naltrexone Combined with a Cognitive Behavioral Treatment Based on the Community Reinforcement Approach. Substance Use and Misuse, 2006, 41, 45-60.	1.4	20
106	Impaired Stroke Volume Response to Exercise in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2006, 47, 1732-1733.	2.8	126
107	Assessing a System to Capture Stray Aerosol during Inhalation of Nebulized Liposomal Cisplatin. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2006, 19, 385-391.	1.2	47
108	Impaired left ventricular filling due to right-to-left ventricular interaction in patients with pulmonary arterial hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H1528-H1533.	3.2	259

#	Article	IF	CITATIONS
109	Traditional Versus Up-Front [¹⁸ F] Fluorodeoxyglucose–Positron Emission Tomography Staging of Non–Small-Cell Lung Cancer: A Dutch Cooperative Randomized Study. Journal of Clinical Oncology, 2006, 24, 1800-1806.	1.6	145
110	Assessment of the Pulmonary Volume Pulse in Idiopathic Pulmonary Arterial Hypertension by Means of Electrical Impedance Tomography. Respiration, 2006, 73, 597-602.	2.6	18
111	Bronchoscopy for Lung Cancer. Chest, 2005, 128, 16-18.	0.8	12
112	The Natural History of Carcinoma In Situ Involving Bronchial Resection Margins. Chest, 2005, 128, 1736-1741.	0.8	20
113	Interventricular Mechanical Asynchrony Due To Right Ventricular Pressure Overload in Pulmonary Hypertension Plays an Important Role in Impaired Left Ventricular Filling. Chest, 2005, 128, 628S-630S.	0.8	48
114	A comparison of noninvasive MRIâ€based methods of estimating pulmonary artery pressure in pulmonary hypertension. Journal of Magnetic Resonance Imaging, 2005, 22, 67-72.	3.4	110
115	Detection and Staging of Preinvasive Lesions and Occult Lung Cancer in the Central Airways with 18F-Fluorodeoxyglucose Positron Emission Tomography: A Pilot Study. Clinical Cancer Research, 2005, 11, 6186-6189.	7.0	24
116	Interventricular Septal Configuration at MR Imaging and Pulmonary Arterial Pressure in Pulmonary Hypertension. Radiology, 2005, 234, 710-717.	7.3	180
117	Prognostic Relevance of Response Evaluation Using [¹⁸ F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 8362-8370.	1.6	243
118	Early Changes of Cardiac Structure and Function in COPD Patients With Mild Hypoxemia. Chest, 2005, 127, 1898-1903.	0.8	138
119	Surgical mediastinal staging in daily practice. Lung Cancer, 2005, 47, 243-251.	2.0	39
120	Second-line for small cell lung cancer: how-to-do-it?. Lung Cancer, 2005, 48, 263-265.	2.0	10
121	The natural course of preneoplastic lesions in bronchial epithelium. Clinical Cancer Research, 2005, 11, 537-43.	7.0	97
122	Cost-Effectiveness of Early Intervention: Comparison between Intraluminal Bronchoscopic Treatment and Surgical Resection for T ₁ N₀ Lung Cancer Patients. Respiration, 2004, 71, 391-396.	2.6	24
123	Combined Use of Autofluorescence Bronchoscopy and Argon Plasma Coagulation Enables Less Extensive Resection of Radiographically Occult Lung Cancer. Respiration, 2004, 71, 410-411.	2.6	9
124	Determinants of pulmonary perfusion measured by electrical impedance tomography. European Journal of Applied Physiology, 2004, 92, 45-49.	2.5	56
125	The performance of 18F-fluorodeoxyglucose positron emission tomography in small solitary pulmonary nodules. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1231-6.	6.4	129

126 Elevated hTERT mRNA levels: A potential determinant of bronchial squamous cell carcinoma (<i>in) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50

#	Article	IF	CITATIONS
127	Bronchial typical carcinoid tumors: histological study of intra- versus extraluminal growth pattern. Lung Cancer, 2004, 44, 129-130.	2.0	1
128	What is early lung cancer?. Lung Cancer, 2004, 45, 267-277.	2.0	31
129	Smoking behavior does not influence the natural course of pre-invasive lesions in bronchial mucosa. Lung Cancer, 2004, 45, 153-154.	2.0	11
130	Effects of Epoprostenol on Right Ventricular Hypertrophy and Dilatation in Pulmonary Hypertension. Chest, 2004, 125, 572-579.	0.8	94
131	Lung Density Measurements in Spontaneous Pneumothorax Demonstrate Airtrapping. Chest, 2004, 125, 2083-2090.	0.8	24
132	Actual and Predicted Postoperative Changes in Lung Function After Pneumonectomy. Chest, 2004, 125, 1735-1741.	0.8	30
133	Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1444-1449.	6.4	114
134	Bronchoscopic treatment of patients with intraluminal microinvasive radiographically occult lung cancer not eligible for surgical resection: a follow-up study. Lung Cancer, 2003, 39, 49-53.	2.0	47
135	Suprabasal p53 immunostaining in premalignant endobronchial lesions in combination with histology is associated with bronchial cancer. Lung Cancer, 2003, 40, 165-172.	2.0	11
136	Multiple suspicious lesions detected by autofluorescence bronchoscopy predict malignant development in the bronchial mucosa in high risk patients. Lung Cancer, 2003, 41, 295-301.	2.0	46
137	Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer. Lung Cancer, 2003, 42, 3-6.	2.0	12
138	Pulmonary Vascular Responses to Hypoxia and Hyperoxia in Healthy Volunteers and COPD Patients Measured by Electrical Impedance Tomographya. Chest, 2003, 123, 1803-1809.	0.8	45
139	Lung Attenuation Measurements in Healthy Young Adults. Respiration, 2003, 70, 143-148.	2.6	4
140	Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet, The, 2002, 359, 1388-1392.	13.7	823
141	Activity of pemetrexed (alimta), a new antifolate, against non-small cell lung cancer. Lung Cancer, 2002, 38, 3-7.	2.0	9
142	Recombinant human interleukin-3 administered concomitantly with chemotherapy in patients with relapsed small cell lung cancer. Journal of Experimental Therapeutics and Oncology, 2002, 2, 47-52.	0.5	1
143	Pemetrexed as a single agent in the therapy of advanced lung cancer. Seminars in Oncology, 2002, 29, 17-22.	2.2	10
144	Fluorescence bronchoscopy for early detection of lung cancer. Lung Cancer, 2001, 34, 157-168.	2.0	54

#	Article	IF	Citations
145	Positron Emission Tomography Scans Can Detect Radiographically Occult Lung Cancer in the Central Airways. Journal of Clinical Oncology, 2001, 19, 4271-4272.	1.6	11
146	Autofluorescence Bronchoscopy Improves Staging of Radiographically Occult Lung Cancer and Has an Impact on Therapeutic Strategy. Chest, 2001, 120, 1327-1332.	0.8	107
147	The Curative Potential of Intraluminal Bronchoscopic Treatment for Early-Stage Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2001, 2, 264-270.	2.6	24
148	Impaired Left Ventricular Filling Due to Right Ventricular Pressure Overload in Primary Pulmonary Hypertension. Chest, 2001, 119, 1761-1765.	0.8	166
149	Mediastinoscopy as a standardised procedure for mediastinal lymph node staging in non-small cell lung carcinoma. European Journal of Cardio-thoracic Surgery, 2001, 19, 377-378.	1.4	13
150	Treatment of Brain Metastases of Small-Cell Lung Cancer: Comparing Teniposide and Teniposide With Whole-Brain Radiotherapy—A Phase III Study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. Journal of Clinical Oncology, 2000, 18, 3400-3408.	1.6	223
151	High-Resolution CT in Patients With Intraluminal Typical Bronchial Carcinoid Tumors Treated With Bronchoscopic Therapy. Chest, 2000, 117, 125-128.	0.8	44
152	Outcome of Bronchial Carcinoma In Situ. Chest, 2000, 117, 1572-1576.	0.8	151
153	Observer Variability in Histopathologic Reporting of Bronchial Biopsy Specimens. Journal of Bronchology, 2000, 7, 210-214.	0.2	32
154	Determination of stroke volume by means of electrical impedance tomography. Physiological Measurement, 2000, 21, 285-293.	2.1	60
155	Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non–Cross-Resistant Schedule. Journal of Clinical Oncology, 1999, 17, 927-927.	1.6	104
156	Results of Two Years Expenience with Fluorescence Bronchoscopy in Detection of Preinvasive Bronchial Neoplasia. Diagnostic and Therapeutic Endoscopy, 1999, 5, 77-84.	1.5	39
157	Curative Endobronchial Therapy in Early-Stage Non-Small Cell Lung Cancer. Journal of Bronchology, 1999, 6, 198-206.	0.2	22
158	Gemcitabine and Paclitaxel: Pharmacokinetic and Pharmacodynamic Interactions in Patients With Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 1999, 17, 2190-2190.	1.6	141
159	Bronchoscopic treatment of intraluminal typical carcinoid: A pilot study. Journal of Thoracic and Cardiovascular Surgery, 1998, 116, 402-406.	0.8	81
160	MRI evaluation of right ventricular pressure overload in chronic obstructive pulmonary disease. Journal of Magnetic Resonance Imaging, 1998, 8, 999-1005.	3.4	48
161	Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study. Radiotherapy and Oncology, 1998, 46, 29-32.	0.6	91
162	Pulmonary perfusion measured by means of electrical impedance tomography. Physiological Measurement, 1998, 19, 263-273.	2.1	51

#	Article	IF	CITATIONS
163	Early Detection of Preinvasive Lesions in High-Risk Patients. Journal of Bronchology, 1998, 5, 280-283.	0.2	61
164	The Effect of Right Ventricular Hypertrophy on Left Ventricular Ejection Fraction in Pulmonary Emphysema. Chest, 1997, 112, 640-645.	0.8	67
165	Long Term Complete Remission of Intraluminal Squamous Cell Carcinoma by Bronchoscopic Electrosurgery. Diagnostic and Therapeutic Endoscopy, 1997, 4, 9-11.	1.5	0
166	Pulmonary Nodules in a Patient With Seminoma Testis. Chest, 1996, 109, 265-266.	0.8	5
167	Videothoracoscopic Appearance of First and Recurrent Pneumothorax. Chest, 1995, 108, 330-334.	0.8	90
168	Prognostic Factors in Patients With Spontaneous Pneumothorax Treated With Video-Assisted Thoracoscopy. Diagnostic and Therapeutic Endoscopy, 1995, 2, 1-5.	1.5	20
169	Video-Assisted Thoracoscopy is Superior to Standard Computer Tomography of the Thorax for Selection of Patients With Spontaneous Pneumothorax for Bullectomy. Diagnostic and Therapeutic Endoscopy, 1995, 2, 89-92.	1.5	5
170	Bronchoscopic Therapy in Patients With Intraluminal Typical Bronchial Carcinoid. Chest, 1995, 107, 556-558.	0.8	103
171	Response and Pattern of Failure After Photodynamic Therapy for Intraluminal Stage I Lung Cancer. Journal of Bronchology, 1994, 1, 295-298.	0.2	49
172	Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: A phase II study of the EORTC lung cancer cooperative group. European Journal of Cancer, 1993, 29, 204-207.	2.8	24
173	A feasibility study of testing new drugs for small-cell lung cancer in patients with a poor performance status. Cancer Chemotherapy and Pharmacology, 1991, 27, 490-491.	2.3	2
174	Staging and Treatment for Small Cell Lung Cancer. , 1991, , 47-60.		5
175	Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. European Journal of Cancer & Clinical Oncology, 1987, 23, 1409-1411.	0.7	142
176	High-dose cyclophosphamide and high-dose VP 16-213 for recurrent or refractory small cell lung cancer. A phase II study. European Journal of Cancer & Clinical Oncology, 1985, 21, 1467-1470.	0.7	4